UK Phase II IMAGO Study
The IMAGO study is a placebo-controlled study to evaluate the safety and efficacy of LUM001 in children with ALGS. The U.K.-based study will enroll children, two years of age and older, with ALGS. Patients that complete the IMAGO will be eligible for participation in a long-term extension study. Further details on the IMAGO study can be found here.
Primary Biliary Cirrhosis
International Phase II CLARITY Study
The CLARITY study is an international, multi-center study that will enroll adult patients with primary biliary cirrhosis experiencing moderate to severe pruritus (itching). The primary endpoint of the study is change from baseline in pruritus compared to placebo. Further details on the CLARITY study can be found here.